Insider Selling: FibroGen Inc (FGEN) Director Sells 1,000 Shares of Stock

FibroGen Inc (NASDAQ:FGEN) Director Roberto Pedro Rosenkranz sold 1,000 shares of the stock in a transaction that occurred on Thursday, March 15th. The stock was sold at an average price of $52.34, for a total transaction of $52,340.00. Following the sale, the director now owns 24,000 shares in the company, valued at approximately $1,256,160. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Roberto Pedro Rosenkranz also recently made the following trade(s):

How to Become a New Pot Stock Millionaire
  • On Friday, January 26th, Roberto Pedro Rosenkranz sold 6,000 shares of FibroGen stock. The stock was sold at an average price of $60.00, for a total transaction of $360,000.00.
  • On Monday, January 22nd, Roberto Pedro Rosenkranz sold 71 shares of FibroGen stock. The stock was sold at an average price of $50.00, for a total transaction of $3,550.00.

Shares of FibroGen Inc (FGEN) traded down $0.05 during trading hours on Friday, reaching $51.15. 932,295 shares of the company traded hands, compared to its average volume of 635,754. The company has a market cap of $4,232.55, a P/E ratio of -28.90 and a beta of 1.76. The company has a debt-to-equity ratio of 0.17, a quick ratio of 9.70 and a current ratio of 9.70. FibroGen Inc has a fifty-two week low of $22.75 and a fifty-two week high of $63.00.

Several analysts recently issued reports on FGEN shares. ValuEngine lowered shares of FibroGen from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. BidaskClub lowered shares of FibroGen from a “hold” rating to a “sell” rating in a research report on Thursday, December 7th. Leerink Swann reiterated an “outperform” rating and set a $88.00 price target (up previously from $80.00) on shares of FibroGen in a research report on Wednesday, February 28th. TheStreet upgraded shares of FibroGen from a “d” rating to a “c-” rating in a research report on Tuesday, February 27th. Finally, Zacks Investment Research downgraded shares of FibroGen from a “hold” rating to a “sell” rating in a research note on Monday, March 5th. Two analysts have rated the stock with a sell rating, three have given a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $66.67.

Large investors have recently modified their holdings of the stock. Bank of Montreal Can lifted its stake in FibroGen by 2,097.2% in the 4th quarter. Bank of Montreal Can now owns 3,186 shares of the biopharmaceutical company’s stock valued at $151,000 after purchasing an additional 3,041 shares during the last quarter. Fortaleza Asset Management Inc. lifted its stake in FibroGen by 95.0% in the 4th quarter. Fortaleza Asset Management Inc. now owns 3,490 shares of the biopharmaceutical company’s stock valued at $165,000 after purchasing an additional 1,700 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in FibroGen by 41.9% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,883 shares of the biopharmaceutical company’s stock valued at $184,000 after purchasing an additional 1,147 shares during the last quarter. Oppenheimer Asset Management Inc. lifted its stake in FibroGen by 112.6% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 4,410 shares of the biopharmaceutical company’s stock valued at $237,000 after purchasing an additional 2,336 shares during the last quarter. Finally, Paloma Partners Management Co bought a new position in FibroGen in the 4th quarter valued at approximately $255,000. 61.39% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This article was first published by Ticker Report and is owned by of Ticker Report. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://www.tickerreport.com/banking-finance/3272774/insider-selling-fibrogen-inc-fgen-director-sells-1000-shares-of-stock.html.

About FibroGen

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Valeura Energy  Insider Sells C$1,580,806.08 in Stock
Valeura Energy Insider Sells C$1,580,806.08 in Stock
Robert Half International  Trading 0.3% Higher  on Analyst Upgrade
Robert Half International Trading 0.3% Higher on Analyst Upgrade
Texas Instruments  Shares Gap Up  on Analyst Upgrade
Texas Instruments Shares Gap Up on Analyst Upgrade
Samuel Adams  Hits New 1-Year High and Low After Strong Earnings
Samuel Adams Hits New 1-Year High and Low After Strong Earnings
Peoples Financial Services  Announces  Earnings Results
Peoples Financial Services Announces Earnings Results
Tupperware Brands  Issues Q2 Earnings Guidance
Tupperware Brands Issues Q2 Earnings Guidance


© 2006-2018 Ticker Report. Google+.